Calendrier des promotions UroGen Pharma Ltd.
Calendrier avancé
Graphique simple
À propos de l'entreprise UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. plus de détails| IPO date | 2017-05-04 |
|---|---|
| ISIN | IL0011407140 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.urogen.com |
| Цена ао | 11.52 |
| Changement de prix par jour: | 0% (10.6) |
|---|---|
| Changement de prix par semaine: | +9.73% (9.66) |
| Changement de prix par mois: | -4.25% (11.07) |
| Changement de prix sur 3 mois: | +6.75% (9.93) |
| Changement de prix sur six mois: | -15.87% (12.6) |
| Changement de prix par an: | -26.85% (14.49) |
| Evolution du prix sur 3 ans: | +34.18% (7.9) |
| Evolution du prix sur 5 ans: | -25.72% (14.27) |
| Evolution des prix depuis le début de l'année: | -6.44% (11.33) |
|
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
|||||||||||||||||||||||||||||||||||||
| Établissements | Volume | Partager, % |
|---|---|---|
| Great Point Partners LLC | 2620545 | 8.49 |
| Menora Mivtachim Holdings Ltd. | 2303031 | 7.46 |
| RA Capital Management, L.P. | 1483697 | 4.81 |
| Blackrock Inc. | 1197647 | 3.88 |
| Credit Suisse Ag/ | 1060000 | 3.43 |
| Harel Insurance Investments & Financial Services Ltd. | 870194 | 2.82 |
| RTW Investments LP | 857464 | 2.78 |
| Migdal Insurance & Financial Holdings Ltd. | 648302 | 2.1 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508883 | 1.65 |
| Wildcat Capital Management, LLC | 495606 | 1.61 |
| ETF | Partager, % | Rentabilité pour l'année, % | Dividendes, % |
|---|---|---|---|
| Future Tech ETF | 0.05533 | 426.34 | 0.8416 |
| Principal Healthcare Innovators ETF | 0.05533 | 618.5 | 0.8416 |
| 0.06 | 522.42 | 0.84 |
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
|---|---|---|---|
| Ms. Elizabeth A. Barrett | President, CEO & Director | 1.12M | 1962 (63 année) |
| Mr. Dong Kim | Chief Financial Officer | 546.68k | 1977 (48 années) |
| Mr. Jason Drew Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | 717.58k | 1972 (53 année) |
| Vincent I. Perrone | Senior Director of Investor Relations | N/A | |
| Mr. Bryon Wornson | Executive Vice President of Talent, Advocacy & Communications | N/A | |
| Dr. Mark P. Schoenberg M.D. | Chief Medical Officer | 579.5k | 1958 (67 années) |
| Mr. James Ottinger R.ph. | Executive Vice President of Regulatory Affairs & Quality | N/A | |
| Dr. Marina Konorty Ph.D. | Executive Vice President of Research & Development and Technical Operations | ||
| Dr. Polly A. Murphy D.V.M., M.B.A., Ph.D. | Chief Business Officer | 1965 (60 années) | |
| Mr. Michael J. Louie M.D., M.P.H., M.Sc. | Senior Vice President of Medical Affairs & Clinical Development |
Adresse: United States, Princeton. NJ, 400 Alexander Park - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.urogen.com
Site web: https://www.urogen.com
